Cogent Biosciences Valuation
| COGT Stock | USD 5.87 0.24 4.26% |
At this time, the firm appears to be overvalued. Cogent Biosciences shows a prevailing Real Value of $5.24 per share. The current price of the firm is $5.87. Our model approximates the value of Cogent Biosciences from analyzing the firm fundamentals such as Shares Owned By Insiders of 0.15 %, return on equity of -1.0, and Current Valuation of 509.33 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cogent Biosciences' price fluctuation is relatively risky at this time. Calculation of the real value of Cogent Biosciences is based on 3 months time horizon. Increasing Cogent Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cogent Biosciences' intrinsic value may or may not be the same as its current market price of 5.87, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.87 | Real 5.24 | Hype 5.87 | Naive 6.88 |
The intrinsic value of Cogent Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cogent Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cogent Biosciences helps investors to forecast how Cogent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cogent Biosciences more accurately as focusing exclusively on Cogent Biosciences' fundamentals will not take into account other important factors: Cogent Biosciences Total Value Analysis
Cogent Biosciences is currently forecasted to have valuation of 509.33 M with market capitalization of 668.33 M, debt of 17.47 M, and cash on hands of 325.56 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cogent Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
509.33 M | 668.33 M | 17.47 M | 325.56 M |
Cogent Biosciences Asset Utilization
One of the ways to look at asset utilization of Cogent is to check how much profit was generated for every dollar of assets it reports. Cogent Biosciences shows a negative utilization of assets of -0.54 percent, losing $0.005378 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cogent Biosciences shows how discouraging it operates for each dollar spent on its assets.Cogent Biosciences Ownership Allocation
The majority of Cogent Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cogent Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cogent Biosciences. Please pay attention to any change in the institutional holdings of Cogent Biosciences as this could imply that something significant has changed or is about to change at the company.Cogent Biosciences Profitability Analysis
Net Loss for the year was (255.86 M) with loss before overhead, payroll, taxes, and interest of (121.63 M).About Cogent Biosciences Valuation
The stock valuation mechanism determines Cogent Biosciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cogent Biosciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cogent Biosciences. We calculate exposure to Cogent Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cogent Biosciences's related companies.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cogent Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
Cogent Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cogent Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 103.9 M |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.